ARRIVE Trial: Daily Aspirin Fails to Lower CV Risk in Long-t
In a moderate-risk population with low event rates, aspirin did not significantly reduce initial vascular events, according to the ARRIVE study presented at the European Society of Cardiology Congress.

Among 12,546 patients randomly assigned to receive enteric-coated aspirin (Bayer) 100 mg daily or placebo and followed for a median of 60 months, the primary efficacy endpoint of time to first occurrence of CV death, MI, unstable angina, stroke or transient ischemic attack occurred in 4.29% of the aspirin group vs. 4.48% of the placebo group, according to results of an intention-to-treat analysis.

All patients enrolled in the ARRIVE study were considered to be at moderate risk based on number of risk factors and were free from diabetes and elevated bleeding risk. Men were aged at least 55 years and women were aged at least 60 years. Enrollment occurred at 501 centers in seven countries.

Read more here:
Dr. P●●●●●r G●●●●●●●h and 1 others like this